DE69009946D1 - System zur transdermalen Albuterol Applikation. - Google Patents

System zur transdermalen Albuterol Applikation.

Info

Publication number
DE69009946D1
DE69009946D1 DE69009946T DE69009946T DE69009946D1 DE 69009946 D1 DE69009946 D1 DE 69009946D1 DE 69009946 T DE69009946 T DE 69009946T DE 69009946 T DE69009946 T DE 69009946T DE 69009946 D1 DE69009946 D1 DE 69009946D1
Authority
DE
Germany
Prior art keywords
patch
application
albuterol
transdermal albuterol
transdermal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69009946T
Other languages
English (en)
Other versions
DE69009946T2 (de
Inventor
Bahram Farhadieh
Rajeeve Dattatrey Gokhale
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GD Searle LLC
Original Assignee
GD Searle LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GD Searle LLC filed Critical GD Searle LLC
Application granted granted Critical
Publication of DE69009946D1 publication Critical patent/DE69009946D1/de
Publication of DE69009946T2 publication Critical patent/DE69009946T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7069—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained otherwise than by reactions only involving carbon to carbon unsaturated bonds, e.g. polysiloxane, polyesters, polyurethane, polyethylene oxide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7092—Transdermal patches having multiple drug layers or reservoirs, e.g. for obtaining a specific release pattern, or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/04—Drugs for genital or sexual disorders; Contraceptives for inducing labour or abortion; Uterotonics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Immunology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DE69009946T 1989-12-04 1990-12-03 System zur transdermalen Albuterol Applikation. Expired - Fee Related DE69009946T2 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US42576689A 1989-12-04 1989-12-04

Publications (2)

Publication Number Publication Date
DE69009946D1 true DE69009946D1 (de) 1994-07-21
DE69009946T2 DE69009946T2 (de) 1994-11-03

Family

ID=23687946

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69009946T Expired - Fee Related DE69009946T2 (de) 1989-12-04 1990-12-03 System zur transdermalen Albuterol Applikation.

Country Status (11)

Country Link
US (2) US5164189A (de)
EP (1) EP0431519B1 (de)
JP (1) JPH07133230A (de)
KR (1) KR910011247A (de)
AT (1) ATE107176T1 (de)
CA (1) CA2031376A1 (de)
DE (1) DE69009946T2 (de)
DK (1) DK0431519T3 (de)
ES (1) ES2055280T3 (de)
IE (1) IE66203B1 (de)
PT (1) PT96059B (de)

Families Citing this family (124)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5679399A (en) 1987-07-17 1997-10-21 Bio Barrier, Inc. Method of forming a membrane, especially a latex or polymer membrane, including multiple discrete layers
US5549924A (en) * 1987-07-17 1996-08-27 Robin Renee Thill Shlenker Method of forming a membrane, especially a latex or polymer membrane, including a deactivating barrier and indicating layer
JPH01153633A (ja) * 1987-12-10 1989-06-15 Kyorin Pharmaceut Co Ltd 経皮吸収製剤
US5633009A (en) * 1990-11-28 1997-05-27 Sano Corporation Transdermal administration of azapirones
US5613958A (en) * 1993-05-12 1997-03-25 Pp Holdings Inc. Transdermal delivery systems for the modulated administration of drugs
US20050152950A1 (en) * 1995-11-13 2005-07-14 Saffran Bruce N. Method and apparatus for macromolecular delivery using a coated membrane
US5708036A (en) * 1996-01-29 1998-01-13 Pesterfield, Jr.; E. Charles Method of treating premature uterine contractions using the optically active R(-)-isomer of albuterol
WO1997026871A1 (en) * 1996-01-29 1997-07-31 Savor, Evelyn Method of treating undesired uterine contractions using optically pure r- or rr-isomers of adrenergic beta-2 agonists
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US6248789B1 (en) 1996-08-29 2001-06-19 Stuart L. Weg Administration of ketamine to manage pain and to reduce drug dependency
GB9719076D0 (en) * 1997-09-09 1997-11-12 Movevirgo Limited A material for producing a medical dressing and a medical dressing produced using the material
CN100357143C (zh) * 1998-01-20 2007-12-26 易通公司 起步发动机扭矩限制
US5900249A (en) * 1998-02-09 1999-05-04 Smith; David J. Multicomponent pain relief topical medication
SE9803240D0 (sv) * 1998-09-24 1998-09-24 Diabact Ab A pharmaceutical composition having a rapid action
KR100369779B1 (ko) * 1999-07-12 2003-01-29 주식회사 엘지생명과학 교감신경 흥분성 기관지확장 약물의 경피흡수 투여용 조성물및 이를 포함하는 경피흡수 투여용 제형
US7713546B1 (en) 2001-04-03 2010-05-11 Soft Gel Technologies, Inc. Corosolic acid formulation and its application for weight-loss management and blood sugar balance
US20070218087A1 (en) * 2001-12-07 2007-09-20 Norbert Hoenzelaer Method of controlled release of vanillin for nasal and/or pulmonary uptake
DE10200578A1 (de) * 2002-01-09 2003-07-10 Roehm Gmbh Haft- und Bindemittel für dermale oder transdermale Therapiesysteme
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
EP1546184A4 (de) * 2002-07-16 2006-08-23 Univ South Florida Humanes immunosuppressives protein
EP2130541A3 (de) 2002-07-29 2013-12-18 Rigel Pharmaceuticals, Inc. Verfahren zur Behandlung oder Vorbeugung von Autoimmunerkrankungen mit 2,4-Pyrimidindiaminverbindungen
US7241456B2 (en) * 2002-10-25 2007-07-10 Australian Importers Ltd. Formulations for topical delivery of bioactive substances and methods for their use
NZ540282A (en) 2002-11-18 2008-06-30 Yaupon Therapeutics Inc Analgesic uses of norketamine and ketamine/norketamine prodrugs
EP1590743A1 (de) * 2003-01-21 2005-11-02 Alza Corporation Rechnerisches modell für die transdermale medikamentenverabreichung
US20060246104A1 (en) * 2003-04-16 2006-11-02 Massia Stephen P Stable rgd peptidomimetic composition
SI1663242T1 (sl) 2003-08-07 2011-09-30 Rigel Pharmaceuticals Inc 2,4-pirimidindiaminske spojine in uporabe kot antiproliferativna sredstva
US20050186269A1 (en) * 2004-02-25 2005-08-25 Udell Ronald G. Stabilized feverfew formulations
US8168600B2 (en) * 2004-04-23 2012-05-01 Isis Pharmaceuticals, Inc. Compositions and methods for topical delivery of oligonucleotides
US20060051435A1 (en) * 2004-08-19 2006-03-09 Udell Ronald G Nutritional supplement for body fat reduction
US9050393B2 (en) 2005-02-08 2015-06-09 Bruce N. Saffran Medical devices and methods for modulation of physiology using device-based surface chemistry
US20070104805A1 (en) * 2005-11-01 2007-05-10 Udell Ronald G Compositions of Hoodia Gordonii and Pinolenic Acid Derivatives
AT502717A1 (de) * 2005-11-09 2007-05-15 Omnica Gmbh Pharmazeutische verwendung einer verbindung
GB0523031D0 (en) * 2005-11-11 2005-12-21 Yaupon Therapeutics Enhancement of morphine analgesia by s(-)-norketamine
CA2642229C (en) 2006-02-24 2015-05-12 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the jak pathway
WO2007100870A2 (en) 2006-02-28 2007-09-07 The Trustees Of Columbia University In The City Of New York Methods for compact aggregation of dermal cells
AT503329A1 (de) * 2006-03-02 2007-09-15 Omnica Gmbh Verfahren zur herstellung einer zusammensetzung, welche zumindest ein xantophyll enthält
AT503521A1 (de) * 2006-05-05 2007-11-15 Omnica Gmbh Verwendung eines extraktes von kiwi-frucht
US8278358B2 (en) * 2006-07-06 2012-10-02 Omnica Gmbh Lipoic acid derivatives
JP2008044926A (ja) * 2006-08-14 2008-02-28 Trustees Of Columbia Univ In The City Of New York Ｗｎｔ信号伝達に関係した分泌タンパク質
DK2089369T3 (da) 2006-10-19 2011-05-09 Rigel Pharmaceuticals Inc 2,4-pyrimidindiaminderivater som hæmmere af JAK-kinaser til behandling af autoimmune sygdomme
US8163902B2 (en) 2006-11-21 2012-04-24 Rigel Pharmaceuticals, Inc. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
US7820207B2 (en) * 2007-03-15 2010-10-26 Omnica Gmbh Stabilized anthocyanin compositions
US8623429B2 (en) 2007-03-15 2014-01-07 Omnica Gmbh Stabilized anthocyanin compositions
CA2587805C (en) * 2007-04-25 2014-02-18 The Procter & Gamble Company Improved vitamin d content uniformity in pharmaceutical dosage forms
US20080293644A1 (en) * 2007-04-27 2008-11-27 Thomas Eidenberger Guava extract
US8034983B2 (en) * 2007-06-06 2011-10-11 Multi-Tech Specialty Chemicals, Co., Ltd. Process for the preparation of xanthophyll crystals
EP2234608A2 (de) 2007-12-11 2010-10-06 Viamet Pharmaceuticals, Inc. Metalloenzymhemmer mit metallbindenden teilen in kombination mit targeting-teilen
WO2009089380A2 (en) * 2008-01-08 2009-07-16 The Trustees Of Columbia University In The City Of New York Methods for p2ry5 mediated regulation of hair growth and mutants thereof
US20090264433A1 (en) * 2008-04-21 2009-10-22 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Triazine Derivatives
US8207205B2 (en) * 2008-04-21 2012-06-26 Institute For Oneworld Health Compounds, compositions and methods comprising oxadiazole derivatives
US20090270398A1 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, Compositions and Methods Comprising Pyridazine Derivatives
WO2009131951A2 (en) * 2008-04-21 2009-10-29 Institute For Oneworld Health Compounds, compositions and methods comprising isoxazole derivatives
MY150599A (en) 2008-08-22 2014-01-30 Sanofi Aventis [4-(5-aminomethyl-2-fluoro-phenyl)-piperidin-1-yl]-[7-fluoro-1-(2-methoxy-ethyl)-4-trifluoromethoxy-1h-indol-3-yl]-methanone as an inhibitor of mast cell tryptase
EP2341776A4 (de) * 2008-09-19 2012-05-30 Inst Oneworld Health Verbindungen, zusammensetzungen und verfahren umfassend imidazol- und triazolderivate
AR074776A1 (es) 2008-12-18 2011-02-09 Sanofi Aventis Metodo para tratar la degeneracion macular; modulando el sistema inmunitario del paciente
CA2746810C (en) 2008-12-30 2017-03-14 Rigel Pharmaceuticals, Inc. Pyrimidinediamine kinase inhibitors
US8324200B2 (en) 2009-01-23 2012-12-04 Rigel Pharmaceuticals, Inc. Compositions and methods for inhibition of the JAK pathway
EP2393488B1 (de) 2009-02-06 2019-06-19 University Of Southern California Therapeutische zusammensetzungen mit monoterpenen
US8511216B2 (en) * 2009-03-30 2013-08-20 Kanzaki Kokyukoki Mfg. Co., Ltd. Hydraulic actuator unit
US8343976B2 (en) * 2009-04-20 2013-01-01 Institute For Oneworld Health Compounds, compositions and methods comprising pyrazole derivatives
RU2561729C2 (ru) 2009-07-08 2015-09-10 Дермира (Канада), Инк. Аналоги tofa, применимые при лечении дерматологических расстройств или состояний
US20110034415A1 (en) 2009-07-20 2011-02-10 Thomas Eidenberger Walnut extracts for nutraceutical applications
FR2955324A1 (fr) 2010-01-15 2011-07-22 Sanofi Aventis [4-(5-aminomethyl-phenyl)-piperidin-1-yl]-1h-indol-3-yl]-methanones disubstituees
EP2493468A1 (de) 2009-10-30 2012-09-05 Sanofi Aminobenzoesäurederivate zur verwendung bei der behandlung von krankheiten im zusammenhang mit dihydrogenase
US20110144200A1 (en) 2009-12-14 2011-06-16 Thomas Eidenberger Combination of carotenoids and epi-lutein
ES2481790T3 (es) 2009-12-23 2014-07-31 Sanofi Profármacos de [4[4-(5-aminometil-2-fluoro-fenil)-piperidin-1-il]-(1H-pirrolo-piridin-il)-metanonas y síntesis de los mismos
RU2012131280A (ru) 2009-12-23 2014-02-10 Санофи [4-(5-аминометил-2-фторфенил)пиперидин-1-ил]-(1н-пирролопиридинил)метаноны и их синтез
WO2011130716A2 (en) 2010-04-16 2011-10-20 Access Pharmaceuticals, Inc. A nanostructures containing vitamin b12 for facilitated delivery of drugs across biological barriers
US20110288093A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, Compositions, and Methods Comprising Pyridazine Sulfonamide Derivatives
US20110288103A1 (en) 2010-04-20 2011-11-24 Institute For Oneworld Health Compounds, compositions, and methods comprising 1,3,4-oxadiazole derivatives
CA2837400C (en) 2010-04-24 2017-12-12 Viamet Pharmaceuticals, Inc. 5-(optionally substituted phenyl) pyridin-2-yl compounds as metalloenzyme inhibitors
KR101937495B1 (ko) 2010-07-28 2019-01-10 리겔 파마슈티칼스, 인크. Ｊａｋ 경로의 억제를 위한 조성물 및 방법
US8685381B2 (en) 2010-10-23 2014-04-01 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
US8968755B2 (en) 2010-10-23 2015-03-03 Joel Schlessinger Topical base and active agent-containing compositions, and methods for improving and treating skin
WO2012058529A2 (en) 2010-10-28 2012-05-03 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
PL2635299T3 (pl) 2010-11-02 2020-03-31 The Trustees Of Columbia University In The City Of New York Sposoby leczenia zaburzeń utraty włosów
KR101848077B1 (ko) 2010-11-13 2018-04-11 이노크린 파마슈티컬즈, 인크. 금속효소 억제제 화합물
JP6071897B2 (ja) 2010-12-13 2017-02-01 イノクリン ファーマシューティカルズ，インコーポレイテッド 金属酵素阻害化合物
EP2678297A2 (de) 2011-02-25 2014-01-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Chrysophaentin-analoga als hemmer des ftsz-proteins
WO2012122313A2 (en) 2011-03-08 2012-09-13 Access Pharmaceuticals, Inc. Targeted nanocarrier systems for delivery of actives across biological membranes
UA114090C2 (uk) 2011-06-19 2017-04-25 Вайамет Фармасьютікалс, Інк. Сполуки, що інгібують металоферменти
US8901121B2 (en) 2011-06-19 2014-12-02 Viamet Pharmaceuticals, Inc. Metalloenzyme inhibitor compounds
CN103857675A (zh) 2011-06-23 2014-06-11 威尔金制药有限公司 金属酶抑制剂化合物
WO2013019169A1 (en) 2011-08-01 2013-02-07 Institute For Oneworld Health Phosphate prodrugs
WO2013033657A2 (en) 2011-09-02 2013-03-07 The Trustees Of Columbia University In The City Of New York CaMKII, IP3R, CALCINEURIN, P38 AND MK2/3 INHIBITORS TO TREAT METABOLIC DISTURBANCES OF OBESITY
EP3351541A1 (de) 2011-12-11 2018-07-25 Viamet Pharmaceuticals (NC), Inc. Metalloenzyminhibitorverbindungen
DK2804858T3 (da) 2012-01-20 2020-03-16 Mycovia Pharmaceuticals Inc Metalloenzym-inhibitorforbindelser
US8877967B2 (en) 2012-03-23 2014-11-04 Oxigene, Inc. Compositions and methods for inhibition of cathepsins
DK2830662T3 (da) 2012-03-29 2019-01-02 Univ Columbia Fremgangsmåder til behandlng af hårtabsforstyrrelser
US20130310340A1 (en) 2012-05-16 2013-11-21 Rigel Pharmaceuticals, Inc. Method of treating muscular degradation
EP2872126B1 (de) * 2012-07-16 2017-12-06 Grünenthal GmbH Pharmazeutisches pflaster zur transdermalen verabreichung von tapentadol
WO2014013014A1 (en) 2012-07-18 2014-01-23 Fundació Privada Centre De Regulació Genòmica (Crg) Jak inhibitors for activation of epidermal stem cell populations
EP2948150A1 (de) 2013-01-25 2015-12-02 Rigel Pharmaceuticals, Inc. Verbindungen und verfahren zur behandlung von darmentzündungskrankheiten
WO2014151734A1 (en) 2013-03-15 2014-09-25 The Trustees Of Columbia University In The City Of New York Fusion proteins and methods thereof
MX2016011517A (es) 2014-03-07 2017-04-13 Univ Arizona Peptidos de crmp2 no narcoticos que seleccionan como diana canales de sodio para el dolor cronico.
WO2015143184A1 (en) 2014-03-19 2015-09-24 Viamet Pharmaceuticals, Inc. Antifungal compound process
EP3778644A3 (de) 2014-12-23 2021-06-02 The Trustees of Columbia University in the City of New York Fgfr-tacc fusionsproteine und verfahren dafür
HRP20221113T1 (hr) 2015-03-19 2022-11-25 Mycovia Pharmaceuticals, Inc. Antifungalni spojevi i procesi izrade
DK3331879T3 (da) 2015-08-04 2020-08-10 Rigel Pharmaceuticals Inc Benzazolforbindelser og fremgangsmåder til fremstilling og anvendelse af forbindelserne
HUE053638T2 (hu) 2015-09-18 2021-07-28 Mycovia Pharmaceuticals Inc Eljárás gombaellenes vegyület elõállítására
US10188750B1 (en) 2015-10-23 2019-01-29 University Of South Florida Self-replicating cell selective gene delivery compositions, methods, and uses thereof
US10464922B2 (en) 2015-12-30 2019-11-05 Nqp 1598, Ltd. Metalloenzyme inhibitor compounds
WO2018005356A1 (en) 2016-06-27 2018-01-04 Rigel Pharmaceuticals, Inc. 2,4-diamino-pyrimidine compounds and method for making and using the compounds
EP3478091B1 (de) 2016-06-29 2024-03-20 Halo Life Science, LLC Verfahren zur herstellung eines geruchsarmen dicholinium-ellagat salzes und anderer geruchsarmer cholinium salze
CN110234637B (zh) 2016-10-26 2022-11-01 里格尔药品股份有限公司 用作irak抑制剂的吡唑酰胺化合物
JP7170634B2 (ja) 2016-10-26 2022-11-14 ライジェル ファーマシューティカルズ， インコーポレイテッド Ｉｒａｋ阻害剤としての使用のためのオキサゾール誘導体およびその調製のための方法
FI3562487T3 (fi) 2016-12-29 2023-12-14 Ji Xing Pharmaceuticals Hong Kong Ltd Metalloentsyymi-inhibiittoriyhdisteitä
EP3562306A4 (de) 2016-12-29 2020-06-24 Selenity Therapeutics (Bermuda), Ltd. Metalloenzym-inhibitor-verbindungen
EP3645525A1 (de) 2017-06-29 2020-05-06 Rigel Pharmaceuticals, Inc. Kinasehemmer und verfahren zu ihrer herstellung und verwendung
US20210292410A1 (en) 2017-12-07 2021-09-23 Morphosys Ag Treatment paradigm for an anti-cd19 antibody and venetoclax combination treatment
WO2019213447A1 (en) 2018-05-03 2019-11-07 Rigel Pharmaceuticals, Inc. Rip1 inhibitory compounds and methods for making and using the same
MD3788045T2 (ro) 2018-05-03 2023-09-30 Rigel Pharmaceuticals Inc Compuși inhibitori ai RIP1 și procedee de obţinere și utilizare a acestora
WO2020092845A1 (en) 2018-11-01 2020-05-07 Rigel Pharmaceuticals, Inc. Method and composition embodiments for treating acute myeloid leukemia
US20200377518A1 (en) 2019-05-29 2020-12-03 Rigel Pharmaceuticals, Inc. Method of preventing and treating thrombosis
JP2022543843A (ja) 2019-08-08 2022-10-14 ライジェル ファーマシューティカルズ， インコーポレイテッド サイトカイン放出症候群を治療するための化合物及び方法
WO2021030526A1 (en) 2019-08-14 2021-02-18 Rigel Pharmaceuticals, Inc. Method of blocking or ameliorating cytokine release syndrome
CN114364674A (zh) 2019-08-30 2022-04-15 里格尔药品股份有限公司 吡唑化合物，其配制品以及使用所述化合物和/或配制品的方法
MX2022002717A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Compuestos inhibidores de rip1 y metodos para prepararlos y usarlos.
MX2022002719A (es) 2019-09-06 2022-08-10 Rigel Pharmaceuticals Inc Inhibidores heterociclicos de la quinasa rip1.
TW202132307A (zh) 2019-11-07 2021-09-01 美商雷傑製藥公司 雜環ｒｉｐ１抑制性化合物
WO2022187303A1 (en) 2021-03-03 2022-09-09 Rigel Pharmaceuticals, Inc. A method for treating a disease or condition using a pyrazole compound or formulation thereof
TW202300490A (zh) 2021-03-11 2023-01-01 美商雷傑製藥公司 雜環rip1激酶抑制劑
TW202346291A (zh) 2022-03-23 2023-12-01 美商雷傑製藥公司 作為ｉｒａｋ抑制劑的嘧啶—２—基—吡唑化合物
WO2023192479A1 (en) 2022-03-31 2023-10-05 Rigel Pharmaceuticals, Inc. Tricyclic irak inhibitors

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3797494A (en) * 1969-04-01 1974-03-19 Alza Corp Bandage for the administration of drug by controlled metering through microporous materials
US4136219A (en) * 1973-02-09 1979-01-23 Odam Norman E Method of applying polyurethane paint to vulcanized rubber
US3935329A (en) * 1973-05-09 1976-01-27 Sheller-Globe Corporation Method of manufacturing new paintable rubber products
US4562075A (en) * 1982-05-20 1985-12-31 Nelson Research & Development Co. Penetration enhancers for transdermal drug delivery of systemic agents
DE2751328A1 (de) * 1976-12-21 1978-06-29 Gen Electric Durch ultraschall verbindbare polyphenylenaether-zusammensetzungen
JPS55139449A (en) * 1979-04-18 1980-10-31 Mitsubishi Gas Chem Co Inc Resin composition
DE3010374A1 (de) * 1980-03-18 1981-10-08 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von copolymerisaten von styrol und/oder dessen derivaten
JPS5812304B2 (ja) * 1980-09-16 1983-03-07 旭化成株式会社 芳香族ポリエ−テル樹脂組成物
DE3102253A1 (de) * 1981-01-24 1982-09-02 Basf Ag, 6700 Ludwigshafen Thermoplastische formmasse
AU564528B2 (en) * 1981-02-26 1987-08-13 General Electric Company Polyphenylene ether compositions and process
US4513120A (en) * 1981-03-23 1985-04-23 General Electric Company Polyphenylene ether compositions
JPS57174344A (en) * 1981-04-21 1982-10-27 Mitsubishi Gas Chem Co Inc Impact-resistant polyphenylene ether resin composition
US4360618A (en) * 1981-11-19 1982-11-23 Monsanto Company Low acrylonitrile content styrene-acrylonitrile polymers blended with polyphenylene oxide
US4435180A (en) * 1982-05-25 1984-03-06 Alza Corporation Elastomeric active agent delivery system and method of use
FR2542998B1 (fr) * 1983-03-24 1986-01-31 Rhone Poulenc Sante Nouvelle forme transdermale du dinitrate d'isosorbide
DE3315272C2 (de) * 1983-04-27 1986-03-27 Lohmann Gmbh & Co Kg, 5450 Neuwied Pharmazeutisches Produkt und Verfahren zu seiner Herstellung
JPS59204650A (ja) * 1983-05-10 1984-11-20 Japan Synthetic Rubber Co Ltd 熱可塑性樹脂組成物
KR860001431B1 (ko) * 1983-07-01 1986-09-24 닛뽕 고오세이 고무 가부시기 가이샤 열가소성 수지 조성물
NL8303497A (nl) * 1983-10-12 1985-05-01 Gen Electric Voorwerp geheel of gedeeltelijk vervaardigd uit een polymeermengsel en voorzien van een polyurethaanlaklaag of een polyurethaanlijmlaag.
US4578423A (en) * 1983-12-12 1986-03-25 Monsanto Company Polyblends of polyphenylene oxide and styrene-acrylonitrile polymers having broad acrylonitrile compositional distribution
US4933184A (en) * 1983-12-22 1990-06-12 American Home Products Corp. (Del) Menthol enhancement of transdermal drug delivery
DE3347277A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
DE3347278A1 (de) * 1983-12-28 1985-07-11 Bayer Ag, 5090 Leverkusen Wirkstoffabgabesysteme
EP0150021A3 (de) * 1984-01-20 1987-07-15 General Electric Company Polyphenylenätherharzzusammensetzungen mit verbessertem Schmelzfliess- und Überzugsvermögen
US4605670A (en) * 1984-02-01 1986-08-12 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering metoclopramide
DE3409079A1 (de) * 1984-03-13 1985-09-19 Bayer Ag, 5090 Leverkusen Medizinische pflaster
CA1248450A (en) * 1984-04-05 1989-01-10 Kazuo Kigasawa Soft patch
EP0177329B1 (de) * 1984-10-05 1992-09-30 Hercon Laboratories Corporation System zur transdermalen Applikation eines Arzneimittels
US4678516A (en) * 1984-10-09 1987-07-07 The Dow Chemical Company Sustained release dosage form based on highly plasticized cellulose ether gels
US4638043A (en) * 1984-11-13 1987-01-20 Thermedics, Inc. Drug release system
DE3586713T2 (de) * 1984-11-15 1993-05-13 Hercon Lab Vorrichtung zur kontrollierten abgabe von arzneimittelwirkstoffen.
CA1272445A (en) * 1985-02-25 1990-08-07 Yie W. Chien Transdermal pharmaceutical absorption dosage unit and process of pharmaceutical administration
US4699777A (en) * 1985-08-21 1987-10-13 Schering Corporation Compositions and method for enhancement of the transdermal flux of albuterol with a combination of 1-dodecyl-azacyclopheptan-2-one and urea
CA1288698C (en) * 1985-08-30 1991-09-10 Yie W. Chien Transdermal anti-anginal pharmaceutical dosage
US4837026A (en) * 1985-10-03 1989-06-06 Rajakhyaksha Vithal J Transdermal and systemic preparation and method
JPH0747535B2 (ja) * 1985-11-26 1995-05-24 日東電工株式会社 消炎鎮痛用貼付剤
JPS6310716A (ja) * 1986-07-02 1988-01-18 Teijin Ltd β−刺激薬外用剤
ZA875317B (en) * 1986-08-01 1988-01-25 Warner-Lambert Company Transdermal compositions
US4906169A (en) * 1986-12-29 1990-03-06 Rutgers, The State University Of New Jersey Transdermal estrogen/progestin dosage unit, system and process
US4814173A (en) * 1987-09-08 1989-03-21 Warner-Lambert Company Silicone elastomer transdermal matrix system
US4820525A (en) * 1987-09-17 1989-04-11 American Home Products Corporation (Del.) Transdermal drug delivery system
US4942037A (en) * 1988-06-02 1990-07-17 Merck & Co., Inc. Transdermal delivery systems

Also Published As

Publication number Publication date
IE904345A1 (en) 1991-06-05
DE69009946T2 (de) 1994-11-03
US5164189A (en) 1992-11-17
CA2031376A1 (en) 1991-06-05
US5290561A (en) 1994-03-01
EP0431519B1 (de) 1994-06-15
KR910011247A (ko) 1991-08-07
PT96059A (pt) 1991-09-30
JPH07133230A (ja) 1995-05-23
EP0431519A1 (de) 1991-06-12
ES2055280T3 (es) 1994-08-16
IE66203B1 (en) 1995-12-13
DK0431519T3 (da) 1994-07-04
PT96059B (pt) 1998-07-31
ATE107176T1 (de) 1994-07-15

Similar Documents

Publication Publication Date Title
ATE107176T1 (de) System zur transdermalen albuterol applikation.
DE3685895D1 (de) Dosierungssystem fuer transdermale absorption von arzneimittelwirkstoffen.
ATE173162T1 (de) Medizinische vorrichtung zur verabreichung von aktivsubstanzen oder arzneistoffen in sehr niedriger dosis, insbesondere von homöopatischen arzneistoffen
DE3872109T2 (de) Vorrichtung zur transkutanen wirkstoffabgabe mit doppeltem durchgangsverstaerker.
DK0429039T3 (da) Anvendelse af en opiat-antagonist til fremstilling af en farmaceutisk sammensætning, der skal indgives transdermalt, samt organ til transdermal afgivelse
DE69637061D1 (de) Neue formulierungen zur transdermalen verabreichung von pergolid
EP0290482A4 (en) Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration
EP0887075A3 (de) Klebstoffmasse zur transdermalen Verabreichung von stark weichmachenden Wirkstoffen
TW252919B (de)
PT93191A (pt) Sistema terapeutico para a administracao retardada e controlada transdermica ou transmucosica de substancias activas
ATE204160T1 (de) Formulierung zur inhalativen applikation
DE69401945D1 (de) Einarbeitung eines poly-n-vinylamids in ein transdermales system
ES2171469T3 (es) Composicion administrada por via nasal y preparacion que la contiene.
ATE259226T1 (de) Zusammmensetzungen und verfahren zur verminderung der atmungsdepressionen und begleitender nebenmwirkungen von mu-opioid-verbindungen
DE59808186D1 (de) Transdermales therapeutisches system zur abgabe von hormonen
DE3587048D1 (de) Pharmazeutische praeparate.
BR9304431A (pt) Medicamento processo para sua preparaçao e aplicaçao de uma mistura
AU625402B2 (en) Transdermal system exhibiting graduated drug release and its use for the local or systemic administration of active substances
DE68929117D1 (de) Chemische Verbindungen und pharmazeutische Zusammensetzungen zur Freisetzung von Arzneimitteln
NO882559L (no) Transdermalt leveringssystem for farmasoeytiske forbindelser.
BR9808876A (pt) Sistema de liberação de medicamento
ATE269063T1 (de) Formulierungen zur transdermalen verabreichung von fenoldopam
RU93004536A (ru) Лекарство для профилактики и терапии неврологических и психиатрических нарушений, возникающих при употреблении алкоголя

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee